Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Regulatory

DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement

By The Northwire Desk — AI Analysis Oct 22, 2025 · 08:35 DTR · 0.43 DiagnosTear Technologies Inc.
DTR · Price

Executive Summary

  • DiagnosTear Technologies Inc. (“DiagnosTear”) is now listed and trading on the Frankfurt Stock Exchange (FSE) under ticker “X8F.”
  • The company has entered into a six‑month marketing services agreement with bullVestor Medien GmbH to promote its FSE listing and increase visibility among European investors.
  • DiagnosTear will pay bullVestor a total fee of €300,000 (≈ $485,000) in installments; bullVestor holds no shares or securities of the company.

Key Details

  • Listing: Common shares commenced trading on the Frankfurt Stock Exchange on October 21, 2025, ticker “X8F.”
  • Purpose of Listing: Expand visibility, broaden European shareholder base, and improve liquidity for DiagnosTear’s stock.
  • Marketing Services Agreement:
  • Provider: bullVestor Medien GmbH (Austria).
  • Term: 6 months starting October 21, 2025.
  • Services include information distribution, media outreach, investor‑relations management, and other promotional activities targeting the German market.
  • Fee: €300,000 total (≈ $485,000), payable in installments.
  • Share Ownership: bullVestor and its principals do not own any DiagnosTear common shares or securities at the time of agreement execution.
  • CEO Quote: “Listing on the Frankfurt Stock Exchange represents a significant milestone for DiagnosTear as we expand our presence in the European capital markets.” – Shimon Gross, CEO.

Notable Quotes

"We are committed to fostering strong relationships with European investors and believe this listing will help us achieve greater visibility and liquidity across the region." – Shimon Gross, CEO, DiagnosTear Technologies Inc.

Read the original news release →

More from DiagnosTear Technologies Inc.

Jun 05, 2026 · 08:31

DiagnosTear’s TeaRx Validation Fails to Halt 65% Decline as CLARIFY Royalties Weigh on Near-Term Upside

Other May 12, 2026 · 16:06

DiagnosTear Solidifies CLARIFY License, Moving from Dry-Eye to Blood Diagnostics, but Commercialization Cliff Looms

Other Feb 26, 2026 · 17:01

DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye

Regulatory Feb 20, 2026 · 17:01

DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical

M&A / Property Jan 22, 2026 · 17:01

DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India

M&A / Property Dec 17, 2025 · 18:01

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Other